You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
PMPA (NMDA antagonist)
Biological Activity for PMPA (NMDA antagonist)
PMPA (NMDA antagonist) is a competitive NMDA receptor antagonist. Displays Ki values of 0.84, 2.74, 3.53 and 4.16 μM at GluN2A, GluN2B, GluN2C and GluN2D subunit-containing receptors respectively. Selective over AMPA receptors.
Please refer to IUPHAR Guide to Pharmacology for the most recent naming conventions.
Technical Data for PMPA (NMDA antagonist)
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for PMPA (NMDA antagonist)
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for PMPA (NMDA antagonist)
The following data is based on the product molecular weight 224.15. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.46 mL||22.31 mL||44.61 mL|
|5 mM||0.89 mL||4.46 mL||8.92 mL|
|10 mM||0.45 mL||2.23 mL||4.46 mL|
|50 mM||0.09 mL||0.45 mL||0.89 mL|
Product Datasheets for PMPA (NMDA antagonist)
References for PMPA (NMDA antagonist)
References are publications that support the biological activity of the product.
Harris and Davies (1992) Cortically evoked excitatory synaptic transmission in the cat red nucleus is antagonised by D-AP5 but not by D-AP7. Brain Res. 594 176 PMID: 1361408
Feng et al (2005) The effect of competitive antagonist chain length on NMDA receptor subunit selectivity. Neuropharmacology 48 354 PMID: 15721167
If you know of a relevant reference for PMPA (NMDA antagonist), please let us know.
View Related Products by Product Action
Keywords: PMPA (NMDA antagonist), PMPA (NMDA antagonist) supplier, Competitive, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, PMPC, 2273, Tocris Bioscience
Citations for PMPA (NMDA antagonist)
Citations are publications that use Tocris products.
Currently there are no citations for PMPA (NMDA antagonist). Do you know of a great paper that uses PMPA (NMDA antagonist) from Tocris? Please let us know.
Reviews for PMPA (NMDA antagonist)
Average Rating: 5 (Based on 1 Review.)
Have you used PMPA (NMDA antagonist)?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
PMPA was in use as an NMDA receptor antagonist affecting glutamate site, to study (possible) competition of dopamine for this site. Application of PMPA and dopamine mixtures in different ratios resulted in a decrease of single-channel NMDA receptor openings recorded from outside-out neuron membrane patches. No problem with dissolution in water up to 10 mM concentration.
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.